CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. CytomX is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its Probody® therapeutic technology platform that could meaningfully improve outcomes for cancer patients. Its proprietary and unique Probody technology platform is designed to enable “conditional activation” of antibody- and cytokine-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation.

CytomX’s robust and differentiated pipeline comprises numerous Probody therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engaging bispecific antibodies, and immune modulators such as cytokines and checkpoint inhibitors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. The company was founded in 2008 and is headquartered in South San Francisco, California.